Management ChangeAug 6, 2026, 07:16 AM
Bausch + Lomb Appoints 4 New Directors, Reaffirms 2026 Guidance
AI Summary
Bausch + Lomb Corporation announced significant changes to its Board of Directors, appointing four new members, including Bausch Health CEO Thomas J. Appio, at the request of its controlling shareholder. Concurrently, four directors resigned, with their departures not attributed to any disagreements. The company also reported strong second-quarter financial results, with revenue increasing to $1.394 billion and net cash from operations significantly improving. Bausch + Lomb reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance.
Key Highlights
- Appointed Thomas J. Appio, Robert Chersi, Laurence Paul, and Barbara Trebbi to Board.
- Steven H. Collis, Karen L. Ling, Thomas W. Ross, and Andrew C. von Eschenbach resigned.
- New appointments were made at the request of controlling shareholder Bausch Health Companies Inc.
- Q2 revenue was $1.394 billion, up 9% reported and 8% constant currency YoY.
- Net cash from operations increased from $32 million in Q1 to $153 million in Q2.
- Reaffirmed full-year 2026 revenue guidance of $5.440 billion to $5.540 billion.
- Reaffirmed 2026 Adjusted EBITDA guidance of $1.025 billion to $1.075 billion.
- Former director Thomas Ross entered a $400,000 consulting agreement for one year.
Price Impact
More from BLCO